The adoption of CRISPR-Cas systems in therapeutics development has led to the rapid emergence of several clinical candidates for treating rare and challenging diseases, including sickle-cell anemia, β ...
Deployment addresses the $1 billion antibody-reproducibility crisis by enabling rapid, objective validation of research reagents, reducing wasted time and cost in research and drug development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback